Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Recruiting now · Phase 1/Phase 2

Conditions studied: Lung Cancer, Nonsmall Cell

In brief

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

Key facts

Study ID

NCT04691817

Run by

Abramson Cancer Center at Penn Medicine

People needed

28

Starts

2023-07-25

Expected to finish

2027-09-01

Last updated by the study team

2026-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
• Prior exposure to at least 1 line of therapy
• Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
• ECOG PS 0-2

You may not qualify if…

• Presence of a driver mutation that is susceptible to targeted therapy
• No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
• Other active invasive malignancy requiring ongoing therapy
• Evidence of progressing or untreated brain metastases
• Evidence or history of leptomeningeal disease
• Uncontrolled tumor related pain
• History of an autoimmune disease or IPF

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.